Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 20 of 22 for “"Nusinersen"”.

  1. Nusinersen Treatment and Healthcare Costs in Spinal Muscular Atrophy

    … have evaluated how the clinical effectiveness of nusinersen, the first FDA approved treatment for SMA, affects healthcare costs. Objective: To assess the effect of nusinersen treatment on healthcare costs in SMA I and SMA Other (SMA types II-IV). Methods: We conducted a retrospective cohort study …

    washington Repository record for Nusinersen Treatment and Healthcare Costs in Spinal Muscular Atrophy (opens in a new tab)

  2. Hand- und Fingerbeugekraftmessungen als sensitiver Funktionsparameter bei Kindern und Erwachsenen mit Spinaler Muskelatrophie unter Therapie mit Nusinersen

    … Bei durchschnittlich 9 Gaben des Medikamentes Nusinersen (entspricht 22 Monaten unter Therapie) und Stabilität oder Abfall der motorischen Testungen stieg die HFK, vor allem die Kraft in Finger III2, über 16 Monate bei Kindern und Erwachsenen mit SMA an. Zusammenfassend ist die Messung der HFK …

    qucosa-diss

  3. Quality of Life of Children With Spinal Muscular Atrophy: Parents’ Perspectives in Light of New Treatments

    … Atrophy (SMA) who received supportive care, nusinersen (Spinraza®), onasemnogene abeparvovec-xioi (Zolgensma®), or both nusinersen and onasemnogene abeparvovec-xioi. Methods: The parents of children with SMA were recruited to complete anonymous online surveys. All surveys included qualitative …

    south-carolina Repository record for Quality of Life of Children With Spinal Muscular Atrophy: Parents’ Perspectives in Light of New Treatments (opens in a new tab)

  4. SMN DEFICIENCY INDUCES NEUROACTIVE AMINOACIDS DYSMETABOLISM: BRIDGING INSIGHTS FROM PRECLINICAL MODELS TO CLINICAL EVIDENCE IN SMA PATIENTS

    … Although disease-modifying therapies such as Nusinersen, Risdiplam, and Onasemnogene abeparvovec have markedly improved survival and motor outcomes, they are not curative, and many patients continue to exhibit residual weakness, metabolic instability, and heterogeneous responses. This …

    milano Repository record for SMN DEFICIENCY INDUCES NEUROACTIVE AMINOACIDS DYSMETABOLISM: BRIDGING INSIGHTS FROM PRECLINICAL MODELS TO CLINICAL EVIDENCE IN SMA PATIENTS (opens in a new tab)

  5. Clinical Translation of Novel Drugs for Rare Paediatric Neurological Diseases

    … for paediatric drug-resistant epilepsy (DRE) and nusinersen for spinal muscular atrophy (SMA). In a time when there was no evidence regarding the use of cannabidiol in paediatric DRE, an EAP was established due to unprecedented patient demand. Our study analysed the safety, adverse effects and …

    unsw Repository record for Clinical Translation of Novel Drugs for Rare Paediatric Neurological Diseases (opens in a new tab)

  6. Systemische Manifestationen der Spinalen Muskelatrophie unter Nusinersentherapie

    … Therapieoptionen mit den Spleißmodifikatoren Nusinersen (seit 2017) und Risdiplam (seit 2021), sowie die Gentherapie Onsasemnogene abeparvovec (seit 2020) ermöglichen ein längeres Überleben der Betroffenen bei aktuell limitierten Erfahrungen zu Langzeiteffekten. Das Ziel dieser Arbeit war es, …

    fu-berlin Repository record for Systemische Manifestationen der Spinalen Muskelatrophie unter Nusinersentherapie (opens in a new tab)

  7. INVESTIGATION OF SMN EXPRESSION IN DEVELOPMENT AND DISEASE: IMPLICATIONS FOR SMA PATHOGENESIS AND TREATMENT

    … intrathecally with the SMN-enhancing drug nusinersen, SMN induction is modest, but highest in younger patients and in caudal CNS regions. In order to identify novel modifiers of SMA disease severity, in Chapter 3 we present a novel bioinformatics algorithm, GENetic moDULators identiFication …

    jhu Repository record for INVESTIGATION OF SMN EXPRESSION IN DEVELOPMENT AND DISEASE: IMPLICATIONS FOR SMA PATHOGENESIS AND TREATMENT (opens in a new tab)

  8. Identifying epigenetic regulators of survival motor neuron protein to treat spinal muscular atrophy

    … the market-approved antisense oligonucleotide nusinersen, is able to prolong the lifespan of severe SMA mice to a greater extent than the oligonucleotide treatment alone. MS023 alters the methylation pattern of hnRNPA1, the main negative regulator of exon 7 inclusion, weakening its binding to …

    oxford Repository record for Identifying epigenetic regulators of survival motor neuron protein to treat spinal muscular atrophy (opens in a new tab)

  9. Descrição de dados de evolução clínica de pacientes com atrofia muscular espinhal 5q tipo 1 antes e após o uso de Nusinersena e/ou de Onasemnogene abeparvovec

    … and divided into two groups: those who used only Nusinersen; and those who initially took Nusinersen but later switched to Onasemnogene abeparvovec. Results: The median age of symptom onset was 3 months (1-5), the median age of Nusinersena initiation was 12 months (1-115) and the median age of …

    brazil-uerj Repository record for Descrição de dados de evolução clínica de pacientes com atrofia muscular espinhal 5q tipo 1 antes e após o uso de Nusinersena e/ou de Onasemnogene abeparvovec (opens in a new tab)

  10. HOW TRADITIONAL DEFINITIONS OF AUTONOMY IMPAIR DECISION-MAKING IN SPINAL MUSCULAR ATROPHY AND ALZHEIMER DISEASE

    … may expose patients to over-treatment with nusinersen, a medication recently approved for the treatment of SMA. Adapting theories of bodily autonomy will allow physicians to approach the treatment of those who cannot verbalize in a more ethical fashion.

    temple Repository record for HOW TRADITIONAL DEFINITIONS OF AUTONOMY IMPAIR DECISION-MAKING IN SPINAL MUSCULAR ATROPHY AND ALZHEIMER DISEASE (opens in a new tab)

  11. Εξελίξεις της γονιδιακής θεραπείας στη νωτιαία μυϊκή ατροφία

    … της πρώτης γενετικής θεραπείας με το σκεύασμα Nusinersen, ήταν η έγκριση από τον FDA, το 2019, της πρώτης γονιδιακής θεραπείας με το onasemnogene abeparvovec-xioi (εμπορική ονομασία Zolgensma). Σύμφωνα με τα μέχρι στιγμής αποτελέσματα, παρατηρήθηκε σημαντική αύξηση προσδόκιμου επιβίωσης στην …

    athens Repository record for Εξελίξεις της γονιδιακής θεραπείας στη νωτιαία μυϊκή ατροφία (opens in a new tab)

  12. Antecedentes y análisis de los impactos de la Ley de presupuestos máximos para las tecnologías No cubiertos en el Plan de Beneficios en Salud.

    … and contemplate the centralized purchase of the Nusinersen drug by ADRES and, in this way, achieve integrated and sustainable attention for Colombians.

    rosario Repository record for Antecedentes y análisis de los impactos de la Ley de presupuestos máximos para las tecnologías No cubiertos en el Plan de Beneficios en Salud. (opens in a new tab)

  13. Targeting the 5' untranslated region of SMN2 as a therapeutic strategy for spinal muscular atrophy

    … encode the fully functional SMN protein. Nusinersen, an FDA-approved therapeutic for SMA, is an antisense oligonucleotide (ASO) that promotes exon 7 inclusion in the SMN2 transcript. The ceiling effect associated with splice-switching approaches makes complementary therapeutic strategies …

    oxford Repository record for Targeting the 5' untranslated region of SMN2 as a therapeutic strategy for spinal muscular atrophy (opens in a new tab)

  14. Contribution of SMN Deficient Skeletal Muscle to Spinal Muscular Atrophy

    … splice switching antisense oligonucleotide (ASO) nusinersen, delivered by lumbar intrathecal injection, targets only the CNS, whereas the splice-switching small molecule risdiplam has widespread distribution. Our laboratory previously demonstrated that increased SMN expression in both motor …

    jhu Repository record for Contribution of SMN Deficient Skeletal Muscle to Spinal Muscular Atrophy (opens in a new tab)

  15. O perfil respiratório de crianças com atrofia muscular espinhal tipo I em uso de terapias modificadoras da doença

    … of children with SMA type 1 undergoing DMT (nusinersen, risdiplam, or onasemnogene abeparvovec). Methods: This is a descriptive, ambidirectional, longitudinal study conducted at the Instituto de Puericultura e Pediatria Martagão Gesteira (IPPMG) of the Federal University of Rio de Janeiro …

    brazil-uerj Repository record for O perfil respiratório de crianças com atrofia muscular espinhal tipo I em uso de terapias modificadoras da doença (opens in a new tab)

  16. The novel strategies of management in paediatric neuromuscular disease: the pathway from diagnosis to treatment.

    … denervation. Therapeutic intervention with nusinersen reduced neurophysiological measures of denervation whilst measures of functional innervation increased with recovery of smaller motor units. To further assess the mechanisms of disease and biological mediators of therapeutic response, …

    unsw Repository record for The novel strategies of management in paediatric neuromuscular disease: the pathway from diagnosis to treatment. (opens in a new tab)

  17. Charakterisierung der Kraft- und anthropometrischen Parameter der Hand, der Finger und des Armes bei Kindern und Jugendlichen mit dem Hand- und Fingerdynamometer HFD 200 und Evaluation der distalen Muskelkraft als funktioneller Marker bei pädiatrisch-neuromuskulären Erkrankungen

    … vor und unter der zielgerichteten Therapie mit Nusinersen untersucht und mit den standardisierten klinischen Motor-Scores verglichen. Ergebnisse: Die Untersuchung der HFK mit dem HFD 200 ist ab einem Alter von 5 Jahren effizient durchführbar. Die physiologische Entwicklung der HFK ist alters- …

    qucosa-diss

  18. Conceptualisations of Movement (and Movement Loss) in New Zealand Adults Living with Spinal Muscular Atrophy: A Critical Analysis

    … for children under 18 to access Spinraza (Nusinersen) and Risdiplam (Evrysidi) respectively. However, New Zealand adults with SMA currently remain without access. While the lack of equity in treatment access is concerning, these pharmaceuticals are not curative. Empirical evidence has shown …

    auckland-tech Repository record for Conceptualisations of Movement (and Movement Loss) in New Zealand Adults Living with Spinal Muscular Atrophy: A Critical Analysis (opens in a new tab)

Page 1 of 2